US20200375937A1 - Mct-based nutrition blend for providing health benefits in animals - Google Patents
Mct-based nutrition blend for providing health benefits in animals Download PDFInfo
- Publication number
- US20200375937A1 US20200375937A1 US16/886,955 US202016886955A US2020375937A1 US 20200375937 A1 US20200375937 A1 US 20200375937A1 US 202016886955 A US202016886955 A US 202016886955A US 2020375937 A1 US2020375937 A1 US 2020375937A1
- Authority
- US
- United States
- Prior art keywords
- animal
- composition
- medium chain
- chain triglycerides
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 241001465754 Metazoa Species 0.000 title claims abstract description 75
- 230000007407 health benefit Effects 0.000 title description 5
- 230000035764 nutrition Effects 0.000 title description 2
- 235000016709 nutrition Nutrition 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 53
- 229940057917 medium chain triglycerides Drugs 0.000 claims abstract description 35
- 230000020763 muscle atrophy Effects 0.000 claims abstract description 20
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 20
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 19
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 18
- 230000004584 weight gain Effects 0.000 claims abstract description 9
- 235000019786 weight gain Nutrition 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims description 37
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 claims description 19
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 17
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 14
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 11
- 235000019197 fats Nutrition 0.000 claims description 11
- 229960002446 octanoic acid Drugs 0.000 claims description 8
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 7
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 241000282326 Felis catus Species 0.000 description 15
- 235000013372 meat Nutrition 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000006014 omega-3 oil Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000021195 test diet Nutrition 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108010068370 Glutens Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000020940 control diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 244000017106 Bixa orellana Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 241000411951 Centrosema virginianum Species 0.000 description 1
- 235000008358 Clitoria ternatea Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 240000002390 Pandanus odoratissimus Species 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 239000010362 annatto Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- -1 sodium bicarbonate, phosphates Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- sarcopenia During aging, there is a gradual decrease in the ability to maintain skeletal muscle function and mass. The condition is known as “sarcopenia.” The exact cause of sarcopenia is unknown, but may be due to a combination of the gradual failure of “satellite cells” that help to regenerate skeletal muscle fibers and a decrease in sensitivity to or the availability of critical secreted growth factors that are necessary to maintain muscle mass and ensure satellite cell survival.
- Methods for combating sarcopenia are known in the art.
- U.S. Pat. No. 7,442,706 disclose methods for treating sarcopenia with growth hormone secretagogues.
- U.S. Pat. Nos. 7,232,580 and 7,138,148 disclose the use of extracts of Ginkgo biloba for preparing a medicament for the treatment of sarcopenia.
- muscle atrophy is defined as a decrease in the mass of the muscle. Muscle atrophy can be a partial or complete wasting away of muscle. When a muscle atrophies, it becomes weaker and, since the ability to exert force is related to mass, loses its ability to effectively support body functions, e.g., motion. Muscle atrophy can be caused by many factors, e.g., diseases such as cancer, AIDS, congestive heart disease, chronic obstructive pulmonary disease, renal failure, and severe burns. Often these animals suffer from “cachexia” and have a poor prognosis for good health or survival. Methods for combating muscle atrophy are known in the art. US20070122821 discloses antisense compositions and methods for treating muscle atrophy. US20060003959 discloses methods and agents for maintaining muscle mass and for preventing muscle atrophy and related biomarkers.
- the present disclosure relates to compositions comprising medium-chain triglycerides and methods comprising administering the compositions to an animal to provide a health benefit. More specifically, the present disclosure relates to compositions that comprise medium-chain triglycerides (MCT) and, in some aspects, can optionally include one or more of omega-3 fatty acids, antioxidants, or arginine.
- MCT medium-chain triglycerides
- the present disclosure also relates to methods for treating sarcopenia or muscle atrophy and to methods of increasing weight gain, increasing fat gain, or maintaining lean body mass in an animal in need thereof by administering the present MCT compositions to the animal.
- the present inventors have discovered that the present MCT compositions can treat sarcopenia or muscle atrophy in an animal as well as increase weight gain, increase fat gain, or maintain lean body mass in an animal in need thereof. Such effect can help treat such animals suffering from cancer, AIDS, congestive heart disease, chronic obstructive pulmonary disease, renal failure, severe burns, and cachexia. Accordingly, in a general embodiment, a method of treating sarcopenia or muscle atrophy in an animal as well as increasing weight gain, increasing fat gain, or maintaining lean body mass in an animal in need thereof is provided. The methods can comprise orally administering a composition comprising a therapeutically effective amount of medium chain triglycerides to the animal.
- “about” is understood to refer to numbers in a range of numerals, for example the range of ⁇ 10% to +10% of the referenced number, preferably within ⁇ 5% to +5% of the referenced number, more preferably within ⁇ 1% to +1% of the referenced number, most preferably within ⁇ 0.1% to +0.1% of the referenced number.
- a range that is “between” two values includes those two values.
- all numerical ranges herein should be understood to include all integers, whole or fractions, within the range.
- these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 1 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
- food means a product or composition that is intended for ingestion by an animal and provides at least one nutrient to the animal.
- the term “pet food” means any food composition intended to be consumed by a companion animal. Such food compositions can include main meal, treats, beverages, supplements, etc.
- the term “companion animal” means a dog or a cat.
- the term “cat” and “feline” can be used interchangeably.
- the term “dog” and “canine” can be used interchangeably.
- the companion animal can be a cat.
- aging means being of advanced age such that the animal has exceeded 50% of the average lifespan for its particular species and/or breed within a species. For example, if the average lifespan for a given breed of dog is 10 years, then a dog within that breed greater than 5 years old would be considered “aging” for purposes herein. Additionally, for example, if the average lifespan for a breed of cat is 15 years, then a cat within that breed greater than 7.5 years old would be considered “aging” for the purposes herein.
- the compositions and methods disclosed herein involve a senior animal, e.g. a senior dog or a senior cat. Animals, such as dogs and cats, are considered senior in the last 25% of their lives.
- the life span of a dog or a cat depends on its size and/or its breed, and a senior dog or senior cat can be determined based on the above calculation but using the numerical value of 75% such that the age threshold is exceeding 75% of the average lifespan.
- “Wet food” means a pet food having a moisture content from about 50% to about 90%, and in one aspect, from about 70% to about 90%.
- “Dry food” means a pet food having a moisture content less than about 20%, and in one aspect, less than about 15%, and in a specific aspect, less than about 10%.
- “Semi-moist food” means a pet food having a moisture content from about 20% to about 50%, and in one aspect, from about 25% to about 35%.
- “Kibbles” means pieces of dry or semi-moist pet food which can have a pellet shape or any other shape. Non-limiting examples of kibbles include particulates; pellets; pieces of pet food, dehydrated meat, meat analog, vegetables, and combinations thereof; and pet snacks, such as meat or vegetable jerky, rawhide, and biscuits.
- compositions disclosed herein may lack any element that is not specifically disclosed herein.
- a disclosure of an embodiment using the term “comprising” includes a disclosure of embodiments “consisting essentially of” and “consisting of” the components identified.
- the methods disclosed herein may lack any step that is not specifically disclosed herein.
- a disclosure of an embodiment using the term “comprising” includes a disclosure of embodiments “consisting essentially of” and “consisting of” the steps identified.
- the description of some steps as “optional” does not imply that the other steps which are not explicitly described as optional are necessarily required.
- prevention includes reduction of risk and/or severity of a condition or disorder.
- treatment includes both prophylactic or preventive treatment (that prevent and/or slow the development of a targeted pathologic condition or disorder) and curative, therapeutic or disease-modifying treatment, including therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder; and treatment of patients at risk of contracting a disease or suspected to have contracted a disease, as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.
- the term does not necessarily imply that a subject is treated until total recovery.
- treatment also refer to the maintenance and/or promotion of health in an individual not suffering from a disease but who may be susceptible to the development of an unhealthy condition.
- treatment,” “treat” and “to alleviate” are also intended to include the potentiation or otherwise enhancement of one or more primary prophylactic or therapeutic measure.
- treatment,” “treat” and “to alleviate” are further intended to include the dietary management of a disease or condition or the dietary management for prophylaxis or prevention a disease or condition.
- a treatment can be patient- or doctor-related.
- the relative terms “improved,” “increased,” “enhanced” and the like refer to the effects of the composition disclosed herein (a composition comprising a therapeutically effective amount of medium chain triglycerides or a prophylactic dose of medium chain triglycerides) relative to a composition having a lower amount or lacking medium chain triglycerides, but otherwise identical.
- therapeutically effective amount means an amount of a compound of the present invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms relating thereto of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
- therapeutically effect amount can refer to the amount to treat any condition relating to a sarcopenia or muscle atrophy.
- long-term administration means periods of repeated administration or consumption in excess of one month. Periods of longer than two, three, or four can be used for certain embodiments. Also, more extended periods that include longer than 5, 6, 7, 8, 9, or 10 months can be used. Periods in excess of 11 months or 1 year can also be used. Longer term use extending over 1, 2, 3, or more years can also be included in the invention. For certain aging animals, the animal will continue consuming on a regular basis for the remainder of its life. Sometimes this is referred to as consumption for “extended” periods.
- regular basis means at least monthly dosing with the compositions or consumption of the compositions, and in some aspects, weekly dosing. More frequent dosing or consumption, such as twice, three, or seven times weekly, can be used in certain embodiments. Still other embodiments include regimens that comprise at least once daily consumption.
- dosing frequency will be a function of the composition that is being consumed or administered, and some compositions may require more or less frequent administration to maintain a desired level of hydration.
- a “medium chain triglyceride” is a lipid in which three fatty acids are bound by ester linkages to a glycerol backbone, and at least two and preferably all three of the fatty acids are each between six and twelve carbons in length.
- the medium-chain fatty acids are caproic acid (comprising six carbon atoms or C6:0), caprylic acid (comprising eight carbon atoms or C8:0), capric acid (comprising ten carbon atoms or C10:0) and lauric acid (comprising twelve carbon atoms or C12:0).
- the medium-chain fatty acids are mainly (e.g., at least 98%) in the form of triglycerides.
- a composition comprising “lipids consisting essentially of medium chain triglycerides” contains medium chain triglycerides as at least 20% of the lipids, in some embodiments at least 30% of the lipids, in other embodiments at least 40% of the lipids, and in some embodiments at least 50% of the lipids in the composition.
- the medium chain fatty acids of the medium chain triglycerides can include at least 50% caprylic acid of the total medium chain fatty acids that are present.
- the medium chain fatty acids of the medium chain triglycerides can include at least 90% caprylic acid of the total medium chain fatty acids that are present.
- the present disclosure relates to compositions comprising medium-chain triglycerides and methods comprising administering the compositions to an animal to provide a health benefit. More specifically, the present disclosure relates to compositions that comprise medium-chain triglycerides (MCT) and, in some aspects, can optionally include one or more of omega-3 fatty acids, antioxidants, or arginine.
- MCT medium-chain triglycerides
- the present disclosure also relates to methods for treating sarcopenia or muscle atrophy and to methods of increasing weight gain, increasing fat gain, or maintaining lean body mass in an animal in need thereof by administering the present MCT compositions to the animal.
- the present inventors have discovered that the present MCT compositions can treat sarcopenia or muscle atrophy in an animal as well as increase weight gain, increase fat gain, or maintain lean body mass in an animal in need thereof. Such effect can help treat such animals suffering from cancer, AIDS, congestive heart disease, chronic obstructive pulmonary disease, renal failure, severe burns, and cachexia. Accordingly, in a general embodiment, a method of treating sarcopenia or muscle atrophy in an animal as well as increasing weight gain, increasing fat gain, or maintaining lean body mass in an animal in need thereof is provided. The methods can comprise orally administering a composition comprising a therapeutically effective amount of medium chain triglycerides to the animal.
- the methods can further include an identifying step for which treatment is sought or for which a health benefit is sought.
- the method can further comprise identifying an animal having sarcopenia or muscle atrophy.
- the method can further comprise identifying an animal in need of one of the following: increase weight gain, increase fat gain, or maintain lean body mass, and combinations thereof.
- the method can further comprise identifying an animal suffering from cancer, AIDS, congestive heart disease, chronic obstructive pulmonary disease, renal failure, severe burns, and cachexia.
- the methods generally comprise orally administering to the animal a composition comprising medium chain triglycerides and optionally one or more of omega-3 fatty acids, antioxidants, and/or an amino acid.
- the composition can further comprise a component selected from the group consisting of an omega-3 fatty acid, antioxidants (including vitamin E, vitamin C, selenium, and/or polyphenols), arginine, and mixtures thereof.
- the composition can be a pet food, such as a wet pet food, a semi-moist pet food, or a dry pet food, e.g., kibble.
- the medium chain triglycerides can be about 0.5 wt % to about 60 wt % of the composition. In one aspect, the medium chain triglycerides can be from about 1 wt % to about 20 wt % of the composition. In other aspects, the medium chain triglycerides can be from about 1 wt % to about 15 wt %, from about 1 wt % to about 10 wt %, or from about 2 wt % to about 10 wt % of the composition.
- the medium chain triglycerides may be prepared by any known process, such as direct esterification, rearrangement, fractionation and/or transesterification.
- the medium chain triglycerides may be prepared from a source of vegetable oil, such as coconut oil, through a rearrangement process.
- the chain length and distribution thereof may vary depending on the source oil.
- MCTs containing 1-10% C6, 30-60% C8, 30-60% C10 and 1-10% C12 can be derived from palm oil and/or coconut oil; in some embodiments, at least a portion of the MCTs are provided by coconut oil, but in other embodiments the composition does not contain coconut oil.
- MCTs containing at least about 95% C8 can be made by semi-synthetic esterification of octanoic acid to glycerin; in some embodiments thereof, the remainder of the fatty acids are C6 and C10.
- the MCTs can include an MCT selected from the group consisting of caprylic acid, capric acid, and a mixture thereof.
- the MCTs can substantially include fatty acids that are caprylic acid (C8).
- such MCTs can include those having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95%, at least 98%, or even 100%, caprylic acid.
- Non-limiting examples of suitable omega-3 fatty acids include eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), and mixtures thereof.
- the omega-3 fatty acids can range from about 0.2 wt % to about 3 wt % of the composition. In some embodiments, the omega-3 fatty acids are at least about 0.2 wt %, at least about 1.0 wt %, or at least about 2.0 wt %.
- the omega-3 fatty acid can be selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), and mixtures thereof.
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- ALA alpha-linolenic acid
- the composition can be administered to the companion animal for a time period of at least one week, at least one month, at least two, three, four, five or six months; and in some embodiments, for at least one year.
- the composition can be administered to the dog at least one day per week, at least two days per week, at least three, four, five or six days per week; or even seven days per week.
- the composition can be administered in a single dose per day or in multiple separate doses per day.
- the composition can be administered in an amount that provides about 0.001 g to 50 g of the MCTs per kg body weight of the companion animal per day. In one aspect, 0.1 g to about 5 g of the MCTs per kg body weight of the companion animal can be administered per day.
- the animal can be a companion animal.
- the companion animal can be a cat.
- the animal can be a senior animal or an aging animal.
- the animal can be a senior cat.
- the animal can be an aging cat.
- the compositions described herein can be pet food compositions.
- the pet food compositions disclosed herein can be any food formulated for consumption by a pet such as a cat.
- the pet food composition provides complete nutrition as defined by the Association of American Feed Control Officials (AAFCO) and which depends on the type of animal for which the composition is intended (e.g., a cat).
- the composition can be a supplement. Such a supplement can be added to a food composition or be administered in conjunction with a food composition, or administered separately.
- the present compositions can be complete and nutritionally balanced pet foods.
- pet food composition can comprise protein, carbohydrates, fat, and ash.
- the pet food compositions comprise from about 15% to about 50% crude protein.
- such compositions may further comprise from about 5% to about 40% fat.
- the compositions may further comprise from about 15% to about 60% carbohydrate.
- the composition may further comprise from about 0.1% to about 15% ash.
- the pet food composition can comprise meat, such as emulsified meat.
- suitable meat include poultry, beef, pork, lamb and fish, especially those types of meats suitable for pets.
- the meat can include any additional parts of an animal including offal.
- Some or all of the meat can be provided as one or more meat meals, namely meat that has been dried and ground to form substantially uniform-sized particles and as defined by AAFCO.
- vegetable protein can be used, such as pea protein, corn protein (e.g., ground corn or corn gluten), wheat protein (e.g., ground wheat or wheat gluten), soy protein (e.g., soybean meal, soy concentrate, or soy isolate), rice protein (e.g., ground rice or rice gluten) and the like.
- the pet food compositions disclosed herein can comprise one or more of a vegetable oil, a flavorant, a colorant or water.
- suitable vegetable oils include soybean oil, corn oil, cottonseed oil, sunflower oil, canola oil, peanut oil, safflower oil and the like.
- the lipids in the composition can consist of the MCTs and one or more of any vegetable oil, any fish oil, the lipid from any meat, and any omega-3 fatty acids.
- Non-limiting examples of suitable flavorants include yeast, tallow, rendered animal meals (e.g., poultry, beef, lamb, pork), flavor extracts or blends (e.g., grilled beef), animal digests, and the like.
- suitable colorants include FD&C colors, such as blue no. 1, blue no. 2, green no. 3, red no. 3, red no. 40, yellow no. 5, yellow no. 6, and the like; natural colors, such as caramel coloring, annatto, chlorophyllin, cochineal, betanin, turmeric, saffron, paprika, lycopene, elderberry juice, pandan, butterfly pea and the like; titanium dioxide; and any suitable food colorant known to the skilled artisan.
- the pet food compositions disclosed herein can optionally include additional ingredients, such as starches, humectants, oral care ingredients, preservatives, amino acids, fibers, prebiotics, sugars, animal oils, aromas, other oils additionally or alternatively to vegetable oil, salts, vitamins, minerals, probiotic microorganisms, bioactive molecules or combinations thereof.
- additional ingredients such as starches, humectants, oral care ingredients, preservatives, amino acids, fibers, prebiotics, sugars, animal oils, aromas, other oils additionally or alternatively to vegetable oil, salts, vitamins, minerals, probiotic microorganisms, bioactive molecules or combinations thereof.
- Non-limiting examples of suitable starches include a grain such as corn, rice, wheat, barley, oats, potatoes, peas, beans, cassava, and the like, and mixtures of these grains, and can be included at least partially in any flour.
- suitable humectants include salt, sugars, propylene glycol and polyhydric glycols such as glycerin and sorbitol, and the like.
- Non-limiting examples of suitable oral care ingredients include alfalfa nutrient concentrate containing chlorophyll, sodium bicarbonate, phosphates (e.g., tricalcium phosphate, acid pyrophosphates, tetrasodium pyrophosphate, metaphosphates, and orthophosphates), peppermint, cloves, parsley, ginger and the like.
- suitable preservatives include potassium sorbate, sorbic acid, sodium methyl para-hydroxybenzoate, calcium propionate, propionic acid, and combinations thereof.
- each additional ingredient in the pet food compositions disclosed herein will depend on a variety of factors such as the ingredient included in the first edible material and any second edible material; the species of animal; the animal's age, body weight, general health, sex, and diet; the animal's consumption rate; the purpose for which the food product is administered to the animal; and the like. Therefore, the components and their amounts may vary widely.
- Yet another aspect of the present disclosure is a method of making a pet food, the method comprising adding MCTs to at least one other comestible ingredient, the MCTs are added in an amount effective to provide the health benefits as disclosed herein.
- the MCTs can be added such that a single serving of the pet food comprises an amount of the MCTs effective to treat or prevent sarcopenia or muscle atrophy.
- compositions and methods using MCTs for controlling or lowering blood pressure or treating kidney or renal disease in a companion animal, in one or more embodiments provided by the present disclosure.
- the average of food for the control group was higher than the test group.
- caloric density of 5.05 kcal/g for the control group and 5.33 kcal/g for the test group
- the caloric intake for the control group was slightly higher than the test group (252 kcal for control vs. 247 kcal for test).
- the test group did not lose lean body mass compared to the control group, shown in Table 3.
- the test group actually increased body fat as compared to the control group, see Table 4, and body weight, see Table 5.
- the results showed that the cats fed the test diet were able to gain more % body fat than the cats fed the control diet (2.66% vs 1.41%).
- the test diet increased body fat in senior cats more than a control diet with identical levels of dietary protein and carbohydrate, and lower level of LCT fat (16% vs 17.15%).
- This finding is unexpected especially because MCTs and omega-3 PUFAs are known for their weight loss benefits.
- the results showed that the cats fed the test diet were able to gain body weight while the cats fed the control diet did not gain any body weight. This observation is opposite to the weight loss benefits of omega-3 PUFAs and MCTs in other species.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Birds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Feed For Specific Animals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/886,955 US20200375937A1 (en) | 2019-05-31 | 2020-05-29 | Mct-based nutrition blend for providing health benefits in animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855045P | 2019-05-31 | 2019-05-31 | |
US16/886,955 US20200375937A1 (en) | 2019-05-31 | 2020-05-29 | Mct-based nutrition blend for providing health benefits in animals |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200375937A1 true US20200375937A1 (en) | 2020-12-03 |
Family
ID=70977553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/886,955 Pending US20200375937A1 (en) | 2019-05-31 | 2020-05-29 | Mct-based nutrition blend for providing health benefits in animals |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200375937A1 (fr) |
EP (1) | EP3934441A1 (fr) |
JP (1) | JP2022534471A (fr) |
CN (1) | CN113840536A (fr) |
AU (1) | AU2020284169A1 (fr) |
BR (1) | BR112021021015A2 (fr) |
CA (1) | CA3140992A1 (fr) |
MX (1) | MX2021013777A (fr) |
WO (1) | WO2020240500A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024068809A1 (fr) * | 2022-09-30 | 2024-04-04 | Société des Produits Nestlé S.A. | Composition et procédé de traitement d'un déclin musculaire associé à une maladie rénale ou à un dysfonctionnement rénal |
WO2024068808A1 (fr) * | 2022-09-30 | 2024-04-04 | Société des Produits Nestlé S.A. | Composition et procédé pour le traitement d'un déclin musculaire associé à une maladie rénale ou à un dysfonctionnement rénal |
WO2024069273A1 (fr) * | 2022-09-30 | 2024-04-04 | Societe Des Produits Nestle Sa | Procédés pour produire des effets bénéfiques sur la santé chez les animaux |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1090636A1 (fr) * | 1999-09-13 | 2001-04-11 | Société des Produits Nestlé S.A. | Régime à haute proportion de lipides |
FR2827518B1 (fr) | 2001-07-17 | 2005-07-08 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie |
US20060003959A1 (en) | 2004-06-10 | 2006-01-05 | Steven Burden | Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same |
EP1855694B1 (fr) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Composition antisens permettant de traiter une atrophie musculaire |
US7442706B2 (en) | 2006-03-15 | 2008-10-28 | Thorner Michael O | Methods for treating sarcopenia with a growth hormone secretagogue |
WO2011078654A1 (fr) * | 2009-12-24 | 2011-06-30 | N.V. Nutricia | Composition nutritionnelle hypocalorique riche en protéines destinée à la stimulation de la synthèse des protéines musculaires |
MX2013009007A (es) * | 2011-02-02 | 2013-08-29 | Nestec Sa | Composiciones nutricionales altas en proteina y metodos para elaborar y utilizar las mismas. |
JP2014512371A (ja) * | 2011-04-18 | 2014-05-22 | ネステク ソシエテ アノニム | α−HICA及びシトルリンを含有する栄養組成物 |
CN102488088A (zh) * | 2011-11-14 | 2012-06-13 | 龙岩新奥生物科技有限公司 | 中链脂肪酸甘油酯及其在微胶囊中的应用 |
RU2681846C2 (ru) * | 2012-08-23 | 2019-03-13 | Нестек Са | Регулирование потери веса и массы тела |
WO2014098193A1 (fr) * | 2012-12-19 | 2014-06-26 | 花王株式会社 | Aliment pour animaux de compagnie |
CA2963350A1 (fr) * | 2014-10-10 | 2016-04-14 | Nestec S.A. | Compositions et procedes permettant d'ameliorer la mobilite ou l'activite ou de traiter une fragilite |
US20170332686A1 (en) * | 2016-05-20 | 2017-11-23 | Nestec Sa | Mct-based nutrition blend for cardiac protection and treating degenerative mitral valve disease in companion animals |
EP3711493A1 (fr) * | 2016-11-16 | 2020-09-23 | Fresenius Kabi Deutschland GmbH | Composition nutritionnelle à utiliser dans la thérapie de patients atteints de fragilité et/ou de sarcopénie ou de pré-sarcopénie ou de fragilité précoce |
WO2019092570A1 (fr) * | 2017-11-09 | 2019-05-16 | Nestec Sa | Mélange nutritionnel pour l'amélioration de la santé chez l'animal |
-
2020
- 2020-05-29 CN CN202080034891.6A patent/CN113840536A/zh active Pending
- 2020-05-29 BR BR112021021015A patent/BR112021021015A2/pt unknown
- 2020-05-29 US US16/886,955 patent/US20200375937A1/en active Pending
- 2020-05-29 JP JP2021563056A patent/JP2022534471A/ja active Pending
- 2020-05-29 CA CA3140992A patent/CA3140992A1/fr active Pending
- 2020-05-29 EP EP20730492.4A patent/EP3934441A1/fr active Pending
- 2020-05-29 MX MX2021013777A patent/MX2021013777A/es unknown
- 2020-05-29 WO PCT/IB2020/055123 patent/WO2020240500A1/fr unknown
- 2020-05-29 AU AU2020284169A patent/AU2020284169A1/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024068809A1 (fr) * | 2022-09-30 | 2024-04-04 | Société des Produits Nestlé S.A. | Composition et procédé de traitement d'un déclin musculaire associé à une maladie rénale ou à un dysfonctionnement rénal |
WO2024068808A1 (fr) * | 2022-09-30 | 2024-04-04 | Société des Produits Nestlé S.A. | Composition et procédé pour le traitement d'un déclin musculaire associé à une maladie rénale ou à un dysfonctionnement rénal |
WO2024069273A1 (fr) * | 2022-09-30 | 2024-04-04 | Societe Des Produits Nestle Sa | Procédés pour produire des effets bénéfiques sur la santé chez les animaux |
Also Published As
Publication number | Publication date |
---|---|
JP2022534471A (ja) | 2022-08-01 |
BR112021021015A2 (pt) | 2021-12-14 |
EP3934441A1 (fr) | 2022-01-12 |
MX2021013777A (es) | 2021-12-10 |
CN113840536A (zh) | 2021-12-24 |
CA3140992A1 (fr) | 2020-12-03 |
AU2020284169A1 (en) | 2021-10-28 |
WO2020240500A1 (fr) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200375937A1 (en) | Mct-based nutrition blend for providing health benefits in animals | |
CA3021169A1 (fr) | Melange nutritionnel a base de triglycerides de chaine moyenne pour la protection cardiaque et le traitement de la valvulopathie mitrale degenerative chez les animaux de compagnie | |
US20190240180A1 (en) | Mct-based nutrition blend for providing health benefits in companion animals | |
US20190373917A1 (en) | Methods and compositions for increasing ketone bodies in animals | |
US20200375934A1 (en) | Mct-based nutrition blend for providing health benefits in animals | |
US10980854B2 (en) | Nutrition blend for health benefits in animals | |
US11925191B2 (en) | Oral compositions and methods for animals | |
US20210022315A1 (en) | Methods and compositions with renal benefits for felines | |
US11648285B2 (en) | Nutrition blend for health benefits in animals | |
RU2786226C2 (ru) | Способы и композиции для повышения содержания кетоновых тел у животных | |
RU2784353C2 (ru) | Питательная смесь для достижения полезных для здоровья эффектов у животных | |
US20240115540A1 (en) | Methods for providing health benefits in animals | |
US20240099334A1 (en) | Compositions and methods for digestive health in an canine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: SOCIETE DES PRODUITS NESTLE S.A., SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PAN, YUANLONG;REEL/FRAME:057513/0301 Effective date: 20190820 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |